BRAINSTORM CELL THERAPEUTICS (BCLI)
US10501E2019 - Common Stock
Overall BCLI gets a fundamental rating of 1 out of 10. We evaluated BCLI against 568 industry peers in the Biotechnology industry. BCLI may be in some trouble as it scores bad on both profitability and health. BCLI does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year BCLI has reported negative net income.
BCLI had a negative operating cash flow in the past year.
In the past 5 years BCLI always reported negative net income.
In the past 5 years BCLI always reported negative operating cash flow.
1.2 Ratios
BCLI has a Return On Assets of -702.62%. This is amonst the worse of the industry: BCLI underperforms 98.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -702.62% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-259.81%
ROA(5y)-239.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for BCLI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for BCLI has been reduced compared to 1 year ago.
Compared to 5 years ago, BCLI has less shares outstanding
BCLI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
BCLI has an Altman-Z score of -179.42. This is a bad value and indicates that BCLI is not financially healthy and even has some risk of bankruptcy.
BCLI's Altman-Z score of -179.42 is on the low side compared to the rest of the industry. BCLI is outperformed by 98.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -179.42 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
BCLI has a Current Ratio of 0.05. This is a bad value and indicates that BCLI is not financially healthy enough and could expect problems in meeting its short term obligations.
BCLI has a Current ratio of 0.05. This is amonst the worse of the industry: BCLI underperforms 99.12% of its industry peers.
A Quick Ratio of 0.05 indicates that BCLI may have some problems paying its short term obligations.
BCLI's Quick ratio of 0.05 is on the low side compared to the rest of the industry. BCLI is outperformed by 99.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.05 | ||
| Quick Ratio | 0.05 |
3. Growth
3.1 Past
BCLI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -685.58%.
EPS 1Y (TTM)-685.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-264.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, BCLI will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.40% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y75.43%
EPS Next 2Y32.86%
EPS Next 3Y21.32%
EPS Next 5Y16.4%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
BCLI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BCLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BCLI's earnings are expected to grow with 21.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.86%
EPS Next 3Y21.32%
5. Dividend
5.1 Amount
No dividends for BCLI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BRAINSTORM CELL THERAPEUTICS
NASDAQ:BCLI (12/20/2024, 8:00:01 PM)
After market: 2.29 +0.01 (+0.44%)2.28
+0.2 (+9.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners15.4%
Inst Owner Change-11.8%
Ins Owners6.11%
Ins Owner Change-0.52%
Market Cap13.00M
Analysts85
Price Target23.29 (921.49%)
Short Float %2.99%
Short Ratio1.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.5%
Min EPS beat(2)-12.04%
Max EPS beat(2)13.04%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-22.6%
PT rev (3m)560.02%
EPS NQ rev (1m)-421.43%
EPS NQ rev (3m)-421.43%
EPS NY rev (1m)0%
EPS NY rev (3m)-1333.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.46
EYN/A
EPS(NY)-2.51
Fwd EYN/A
FCF(TTM)-1.99
FCFYN/A
OCF(TTM)-1.99
OCFYN/A
SpS0
BVpS-1.06
TBVpS-1.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -702.62% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-259.81%
ROA(5y)-239.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.05 | ||
| Quick Ratio | 0.05 | ||
| Altman-Z | -179.42 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)48.02%
Cap/Depr(5y)122.11%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-685.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-264.29%
EPS Next Y75.43%
EPS Next 2Y32.86%
EPS Next 3Y21.32%
EPS Next 5Y16.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.56%
EBIT Next 3Y6.39%
EBIT Next 5Y33.99%
FCF growth 1Y44.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.84%
OCF growth 3YN/A
OCF growth 5YN/A